Hinrich Abken

University Hospital Regensburg — Germany

Medicine · Health Sciences

63h-index13.0kcitations354works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(256), Immune Cell Function and Interaction(110), Immunotherapy and Immune Responses(91), Virus-based gene therapy research(62), Viral Infectious Diseases and Gene Expression in Insects(56)

Publications350 total

Automated GMP-compatible production of universal CAR Tregs for organ-targeted tolerance induction
Journal of Translational Medicine·2025Open Access
Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas
Transfusion Medicine and Hemotherapy·2025Open Access
In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>
Human Gene Therapy·2025Open Access
Development of antigen multimers for detection and evaluation of CAR T cells
Cancer Immunology Immunotherapy·2025Open Access
<scp>LMP2A</scp> ‐Targeting <scp>CAR</scp> ‐T Cells Equipped With Inducible <scp>IL</scp> ‐18 to Address <scp>EBV</scp> ‐Associated Malignancies
HLA·2025Open Access
Automated GMP-Compatible Production of Universal CAR Tregs for Organ-Targeted Tolerance Induction
2025Open Access
CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma
International Journal of Molecular Sciences·2025Open Access
Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager
Journal of Molecular Medicine·2025· 5 citedOpen Access
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy
Journal for ImmunoTherapy of Cancer·2025Open Access
CAR-T-Zellen bei soliden Tumoren – Mechanismen der Resistenz
Die Innere Medizin·2025
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion
Cells·2025Open Access
Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy
2025· 1 citedOpen Access
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges
Nature Reviews Gastroenterology & Hepatology·2025· 13 cited
The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding properties
Molecular Therapy·2025
Weal and woe of interleukin-18 in the T cell therapy of cancer
Journal for ImmunoTherapy of Cancer·2025· 9 citedOpen Access
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function
Journal for ImmunoTherapy of Cancer·2024· 11 citedOpen Access
Development of antigen-dextramers for detection and evaluation of CAR T cells
2024· 1 citedOpen Access
250 Harnessing anti-CD44v6 CAR-NK cells for effective head and neck squamous cell carcinoma treatment
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma
Frontiers in Immunology·2024· 9 citedOpen Access
Data from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
2024Open Access
page 1 of 18Next →

Frequent Co-authors

Andreas Hombach(24), Markus Chmielewski(18), Barbara Seliger(5), Gunter Rappl(5), Claudia Heuser(4), Christoph Pohl(4), David E. Gilham(3), Caroline Kopecky(2), Felix Bohne(2), Ulrike Protzer(2), Tobias Riët(2), Rolf Kiessling(2), Reno Debets(2), Robert E. Hawkins(2), David M. Kofler(2), Anja Hombach(2), Astrid Holzinger(2), Niels Schaft(2), Jan Dörrie(2), D. Koch(2)